Hisse M. van Santen – VJRegenMed

Research projects within the EN-ACTI2NG program

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Hisse M. van Santen, PhD, Centro Biologia Molecular Severo Ochoa, Madrid, Spain, gives an overview of the current research projects within the EN-ACTI2NG program. Dr van Santen describes the research into DNA and RNA aptamers to enhance the response of T-cells. Dr van Santen also discusses the research project comparing the performance of CAR T-cells and TCR T-cells against the same tumor antigen. Additionally, he highlights the project investigating how T-cells interact with their targets. This is particularly important to understand in order to develop new strategies to improve immunotherapies, such as CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.

EN-ACTI2NG program: from TCRs to CARs

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Hisse M. van Santen, PhD, Centro Biologia Molecular Severo Ochoa, Madrid, Spain, discusses the EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of chimeric antigen receptor (CAR) and T-cell receptor (TCR) Interactions and Nanoscale Geometry) and the research currently being undertaken by students into CAR T-cells. Research in the EN-ACTI2NG program investigates key questions about CARs, such as how signaling works, how these cells can be improved and what makes some CARs better than others. Dr van Santen also outlines the benefits and insights students can gain into the medical research industry in Europe through the EN-ACTI2NG program. This interview took place during the 3rd European CAR T-cell Meeting.

The progression of research into CAR T-cell therapy

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Hisse M. van Santen, PhD, Centro Biologia Molecular Severo Ochoa, Madrid, Spain, shares his highlights from the 3rd European CAR T-cell meeting and discusses how research into CAR-T cell therapy has changed and which aspects of CAR-T cell therapy are currently being focused on. This interview took place during the 3rd European CAR T-cell Meeting.